Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synteract Agrees to Acquire Multinational CRO HCR

Published: Friday, December 28, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Gains resources and scale to support large, global CRO programs.

Synteract has entered into a definitive agreement under which Synteract will acquire Harrison Clinical Research (“HCR”).

Harrison Clinical Research, founded in 1987, is headquartered in Munich, Germany and has operations in Europe, Israel and South America in addition to a U.S. office in Princeton, New Jersey.

Synteract plans to combine operations to become a top tier global service provider.

The acquisition of Harrison Clinical Research will give Synteract additional resources and scale to support large, global programs. It also gains a clinical in-patient unit in Germany and a clinical research training center in Belgium.

HCR’s robust early phase and clinical pharmacology services, proven Phase II-IV capabilities, and strong functional service provision will enable the new organization to diversify and deepen its clinical development offerings across therapeutic areas and the spectrum of clinical trials.

However, a continued directive of the new combined company will be to maintain a strong connection with emerging to midsize biopharmaceutical companies where both Synteract’s and HCR’s consultative approach and clinical development expertise has been the mainstay of their respective relationships with customers.

Wendel Barr, Synteract’s CEO, will lead the combined companies. Dr. Francisco Harrison, HCR’s chairman and founder, will remain a senior member of the executive team and become a member of the Board of Directors.

The existing management of HCR will stay in place including CEO Benedikt van Nieuwenhove, who will become head of Europe after the closing of the transaction.

“Harrison Clinical Research is an exceptional fit for Synteract, uniting two well-respected players with longstanding drug development expertise to form a new global leader with enhanced scale and therapeutic breadth,” said Mr. Barr.

Mr. Barr continued, “Together we will provide a continuum of service that allows us to work with clients throughout their entire development life cycle, from emerging products through post-marketing.”

Dr. Harrison stated, “HCR has a long tradition of outstanding customer service, as does Synteract. We see this as a growth opportunity that allows us to continue providing our customers with the same personalized service they have come to expect, but on a larger geographic scale. Our shared company cultures and flexible, customizable approaches to managing clinical trials make this a natural fit for us and ensure our clients will continue receiving the same expertise and excellent customer service worldwide.”

Both companies share a common culture of operational excellence and have a proven track record of success in all phases of clinical development. With the addition of HCR staff, Synteract will have a staff of over 800 in 16 countries.

The transaction is subject to customary closing conditions, including completion of final documentation and receipt of financing, and is expected to close early in the first quarter of 2013.

Synteract is a portfolio company of Gryphon Investors, a San Francisco-based premier middle market private equity firm, which is the lead financial partner in the acquisition. Terms of the transaction were not disclosed.

Alex Earls, a partner and head of Gryphon’s Business Services Group stated, “We are delighted to support the highly strategic acquisition of Harrison Clinical Research, which shares Synteract’s commitment to delivering responsive, customized clinical research services to biopharmaceutical and medical device customers.

The acquisition provides Synteract with a strong geographic presence in Western and Eastern Europe and an emerging presence in South America. Importantly, this acquisition will allow Synteract to more effectively meet the global trial needs of its customer base and brings significant adaptive trial, medical device and nutraceutical expertise to the combined company.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!